Immutep 과거 수익 실적

과거 기준 확인 0/6

Immutep의 수입은 연평균 -20.4%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 19.1%의 비율로 증가했습니다. 매출은 연평균 26%의 비율로 감소해 왔습니다.

주요 정보

-20.4%

수익 성장률

4.2%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	-26.0%
자기자본 수익률	-22.5%
순이익	-1,111.9%
최근 수익 업데이트	30 Jun 2024

최근 과거 실적 업데이트

업데이트 없음

Recent updates

수익 및 비용 분석

Immutep 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

OTCPK:PRRU.F 수익, 비용 및 수입 (AUD Millions )
날짜	수익	수익	G+A 비용
30 Jun 24	4	-43	9
31 Mar 24	4	-42	9
31 Dec 23	4	-41	9
30 Sep 23	4	-40	9
30 Jun 23	4	-40	9
31 Mar 23	4	-38	8
31 Dec 22	4	-37	7
30 Sep 22	5	-34	7
30 Jun 22	5	-32	7
31 Mar 22	4	-29	7
31 Dec 21	4	-26	7
30 Sep 21	4	-28	7
30 Jun 21	4	-30	6
31 Mar 21	5	-29	6
31 Dec 20	6	-27	6
30 Sep 20	10	-20	6
30 Jun 20	14	-13	6
31 Mar 20	13	-15	6
31 Dec 19	13	-16	6
30 Sep 19	9	-17	6
30 Jun 19	6	-18	6
31 Mar 19	5	-18	6
31 Dec 18	5	-17	7
30 Sep 18	6	-15	7
30 Jun 18	7	-13	7
31 Mar 18	6	-12	7
31 Dec 17	7	-10	6
30 Sep 17	5	-9	5
30 Jun 17	4	-9	4
31 Mar 17	3	-10	5
31 Dec 16	2	-10	5
30 Sep 16	2	-36	30
30 Jun 16	2	-62	54
31 Mar 16	2	-71	54
31 Dec 15	1	-82	54
30 Sep 15	1	-57	30
30 Jun 15	1	-32	6
31 Mar 15	1	-23	5
31 Dec 14	1	-14	5
30 Sep 14	2	-14	5
30 Jun 14	2	-13	4
31 Mar 14	2	-13	4
31 Dec 13	2	-13	5

양질의 수익: PRRU.F 은(는) 현재 수익성이 없습니다.

이익 마진 증가: PRRU.F 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: PRRU.F 은(는) 수익성이 없으며 지난 5년 동안 연간 20.4% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 PRRU.F 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: PRRU.F 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 16.6% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: PRRU.F 현재 수익성이 없기 때문에 마이너스 자본 수익률( -22.54% )을 갖습니다.

Immutep 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Recent updates

Immutep Limited, Annual General Meeting, Nov 22, 2024

Immutep Limited Announces Resignation of Anne Anderson as Independent Non-Executive Director

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

Immutep Limited Announces New Data from Eftisarc-Neo Phase II Evaluating Novel Triple Combination Including Immutep's Efti in Soft Tissue Sarcoma

Immutep Limited Announces Positive Efficacy and Safety Results from the TACTI-003 Phase IIb Trial Evaluating Eftilagimod Alpha

Immutep Limited Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress

Immutep Announces First Participant Dosed in Phase I Study of Imp761, A First in Class Agonist Lag-3 Antibody

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

Immutep Limited Receives Regulatory Clearance for Phase I Study of First-In-Class Lag-3 Agonist Antibody Designed to Treat Autoimmune Diseases

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative Pd-L1 Expression

Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial

Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024

Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761

Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti

Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer

Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023

Immutep Limited Announces Excellent New Clinical Data from the TACTI-002 / KEYNOTE-798 Phase II Trial Evaluating Eftilagimod Alpha

Immutep Limited Announces Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Immutep Limited, Annual General Meeting, Oct 24, 2023

Immutep Limited Receives Positive Scientific Advice from Committee for Medicinal Products for Human Use of European Medicines Agency for Continued Development of Eftilagimod Alpha

Immutep Limited Announces First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Immutep Limited Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

Immutep Limited Announces Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

Immutep Limited Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

Immutep Limited Announces Update on INSIGHT-003 Trial in NSCLC

Immutep Limited Enrolls and Randomised over 50% of the Planned 154 Patients in the Tacti-003 Phase IIB Trial

Immutep Limited Announces the Results of Positive Follow-Up Type C Meeting with the US Food and Drug Administration

Immutep Limited Announces the Successful Scale-Up of the Manufacturing of its Lead Product Candidate Eftilagimod Alpha

Immutep Limited Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

Immutep Limited Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

Immutep Limited Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

Immutep Limited Announces the United States Food and Drug Administration (Fda) Has Granted Fast Track Designation to Eftilagimod Alpha

Immutep Limited, Annual General Meeting, Nov 23, 2022

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Appoints Frederic Triebel as Executive Director

Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

Immutep Limited Grants Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor

Immutep Limited Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC

Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates, eftilagimod alpha and IMP76 for the Quarter Ended 30 June 2022

Immutep Limited Reports Positive Overall Response Rate in Its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers

Immutep Limited Announces Executive Changes

Immutep Limited Presents New and Significant Data from the AIPAC Study

Immutep Limited Provides Update on the Ongoing Development of Its Product Candidates, Eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2022

Immutep’S Efti in Combination with Msd’S Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2Nd Line Metastatic Lung Cancer Patients

Immutep Limited Announces New Interim Data in 2nd Line Metastatic NSCLC from Its Phase II TACTI-002 Trial

Immutep Limited Appoints Lucy Turnbull as Non-Executive Director

Immutep Limited to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022

Immutep Limited to Present New Data from the Phase II TACTI-002 Study of Efti At ESMO's European Lung Cancer Congress 2022

Immutep Limited Announces Demise of Grant Chamberlain, Non-Executive Director

Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates, Eftilagimod Alpha

Immutep Limited Reports Good Safety from First Five Patients in the INSIGHT-003 study

Immutep to Present Final Overall Survival Data from Phase IIb AIPAC as a Late Breaking Poster Presentation At SITC 2021

Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates

Immutep Receives FDA and IRB Approval in the US for Phase IIb TACTI-003 Trial in HNSCC

Immutep Limited Signs Agreement to Commence New Phase I Trial, Called Insight-003, to Evaluate the Combination of Lead Product Candidate Eftilagimod Alpha

Immutep Limited Reveals a New anti-LAG-3 Research Program

Immutep Limited Reports Positive Data from Its Tacti-002 Phase Ii Study of Lag-3 Therapy, Efti, At Asco 2021

Immutep Limited Reports Positive Final Data from Insight-004 Trial

Immutep Limited Announces Publication of TACTI-002 and INSIGHT-004 Abstracts for ASCO 2021 Annual Meeting

Immutep Limited Provides an Update on its Clinical and Preclinical Programs

Immutep Limited Enters Second Collaboration with Merck & Co., Inc. for New Randomised Phase IIB Trial in Head and Neck Cancer

Immutep Limited Expands Part B of TACTI-002 Collaboration Trial

Immutep Limited Announces Advancement of Phase II Trial for Eftilagimod Alpha in COVID-19 Patients to Randomised Portion of the Study

Immutep Limited Completes Safety Run-In Data Review of the First Six Patients from the Phase Ii Clinical Trial of Eftilagimod Alpha Treatment by Immune Modulation in COVID-19 Disease

Immutep Limited Discontinues its Phase II Clinical Trial Evaluating an Anti-Lag3 Cell Depleting Monoclonal Antibody, GSK2831781

Immutep Limited Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study